Favrille’s Acquisition Of Diversa CD20 Antibodies Bolsters Lead Lymphoma Program
This article was originally published in The Pink Sheet Daily
Executive Summary
Another firm developing a therapeutic vaccine for lymphoma, Biovest, says it hopes to launch its BiovaxID product in mid-2009.